How to Prepare Performance Verification Documentation for Malaysia MDA Medical Device Registration? (FAQ)

Direct Answer

For medical device registration with the Medical Device Authority (MDA) of Malaysia, performance verification documentation should be prepared as part of a consistent technical file that supports the product's classification, intended use, risk level, and regulatory pathway. The typical dossier includes product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, and local representative arrangements. Companies should first conduct a documentation gap assessment to determine whether existing NMPA, CE, FDA, or other market materials can be reused, and what must be translated, localized, supplemented, or newly generated for Malaysia.

Published: 2026-07-10 11:02; Updated: 2026-07-10 11:02.

Key Summary

Malaysia MDA medical device registration documentation is usually prepared around product classification, technical file, ISO 13485 quality system, performance verification, risk management, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, and local representative arrangements. Companies should first perform a documentation gap assessment, then judge whether existing NMPA, CE, or other market materials can be reused. For Chinese medical device companies, a prudent approach is to first conduct product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market materials can be reused.

Target market registration typically affects the technical file, authorized representative, importer cooperation, labelling language, quality system evidence, and subsequent change maintenance at the same time. If a company proceeds only by asking 'which documents should be submitted,' it may face deficiency letters or rework related to model coverage, evidence chain consistency, labelling claims, and certificate control. AIMEILI recommends that companies plan this issue within a unified GHWP member state and multi-country market access strategy, using one set of reusable core technical documents to support localization in different markets, rather than redoing documentation from scratch for each country.

Applicable Scenarios and Core Questions

Companies searching for 'how to prepare performance verification documentation for Malaysia medical device registration' are usually not seeking a conceptual explanation. They want to judge whether existing documentation can support a target market submission, whether a local agent or authorized representative is needed, why timelines are extended, and which issues may affect launch plans. Behind this question are often product classification, registration pathway, evidence chain, labelling localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, or Latin America at the same time, answering the process for one country alone is not enough. A more valuable approach is to first develop reusable versions of core technical documents, quality system evidence, performance verification, clinical evidence, and labelling, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended purpose, mechanism of action, use scenario, body contact, duration of use, sterility, whether it is active, and whether it contains software or has IVD attributes, and then determine the risk class and submission pathway. If the pathway is wrongly determined, subsequent translation, notarization, authorization, testing, and supplementary documentation will all deviate from the correct direction.

For target market projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely in commercial contracts, market control may be affected later.

Documentation and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer's declarations, and post-market surveillance materials.

The key to documentation quality is not quantity but consistency. Instructions for use claims, model coverage in test reports, scope of clinical evidence, risk management conclusions, labelling warnings, and registration application form information must support each other. Regulators focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded many documents.

Common Mistakes

• Treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Directly translating domestic NMPA documents and submitting them without rearranging evidence according to the target market pathway.
• Having too many model specifications while test reports, clinical evidence, or labelling coverage is insufficient.
• Selecting a local agent only for sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistency among labelling, instructions for use, promotional materials, and registration dossier claims, leading to deficiency letters or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, resulting in repeated preparation for each country and inflated costs and timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation basis and avoid discovering critical evidence gaps only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions for use.
• Confirm the responsibilities, fees, certificate control, and exit mechanism of the local agent or authorized representative.
• Establish a target country gap assessment table and identify what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view target market registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, first establishing a clear set of core technical documents and an evidence matrix, and then converting them according to national requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than filling in documents country by country at short notice.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears voluminous, the project may still face repeated issues during deficiency responses, agent communication, and post-market maintenance.

Frequently Asked Follow-up Questions

Can domestic Chinese documentation be used directly for target market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as is. Companies need to adjust the document structure, language, labelling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to initiate a gap assessment?

It is recommended to initiate it immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, labelling adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent usually participates in registration communication, changes, renewals, and post-market event handling. Unclear responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger to manage the product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This helps identify documentation gaps in a timely manner and enables management to judge whether the project will affect launch plans.

For companies that already have registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. In particular, labelling and instructions for use, clinical evaluation, risk management, performance verification, and quality system certificates must remain version-consistent.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators usually check whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model specifications, instructions for use version, and test reports are inconsistent, even if a large number of documents have been prepared, the company may be asked for supplementary explanations.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and instructions for use version, and quality system certificate item by item. This action may seem basic, but it can significantly reduce the probability of deficiency letters, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

Target market registration projects usually involve local agent, authorized representative, importer, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, instructions for use, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, labelling versions, and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance. Later, when a manufacturing address changes, models are expanded, instructions for use are updated, or the agent is replaced, the certificate may become disconnected from market sales.

AIMEILI recommends that companies manage this issue within an annual international registration plan: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only to improve registration efficiency in a single country, but more importantly to help companies build a replicable overseas compliance capability and reduce the cost of starting from scratch each time they enter a new market.

Further Reading

Previous: What are the requirements for risk management documents for Malaysia medical device registration? Next: What if quality system evidence is inconsistent for Malaysia medical device registration?

Recommended reading:

• How to Prepare Registration Documents for Malaysia Medical Device Registration?
• How to Determine Product Classification for Malaysia Medical Device Registration?
• How to Organize the Technical File for Malaysia Medical Device Registration?
• How to Localize Labelling and Instructions for Use for Malaysia Medical Device Registration?
• How to Prepare Clinical Evaluation Documents for Malaysia Medical Device Registration?
• Can Test Reports Be Reused for Malaysia Medical Device Registration?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundary

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary judgment. Applicability boundary: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country regulatory authority, testing conclusions, or legal opinions. Compiled based on AIMEILI regulatory practice resources, international medical device registration reference materials, and public regulatory information; specific projects should be based on the latest requirements of the target country regulatory authority and the product documentation basis.